Aligos Therapeutics (ALGS) Cash & Equivalents (2021 - 2025)
Historic Cash & Equivalents for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $99.1 million.
- Aligos Therapeutics' Cash & Equivalents rose 3230.97% to $99.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.1 million, marking a year-over-year increase of 3230.97%. This contributed to the annual value of $37.0 million for FY2024, which is 7273.7% down from last year.
- Per Aligos Therapeutics' latest filing, its Cash & Equivalents stood at $99.1 million for Q3 2025, which was up 3230.97% from $122.9 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Cash & Equivalents registered a high of $239.7 million during Q3 2021, and its lowest value of $37.0 million during Q4 2024.
- In the last 5 years, Aligos Therapeutics' Cash & Equivalents had a median value of $99.1 million in 2025 and averaged $116.5 million.
- In the last 5 years, Aligos Therapeutics' Cash & Equivalents surged by 6682.11% in 2023 and then crashed by 7273.7% in 2024.
- Over the past 5 years, Aligos Therapeutics' Cash & Equivalents (Quarter) stood at $186.8 million in 2021, then tumbled by 56.46% to $81.3 million in 2022, then skyrocketed by 66.82% to $135.7 million in 2023, then plummeted by 72.74% to $37.0 million in 2024, then surged by 167.86% to $99.1 million in 2025.
- Its Cash & Equivalents was $99.1 million in Q3 2025, compared to $122.9 million in Q2 2025 and $137.9 million in Q1 2025.